Matrix stiffness-induced IKBKE and MAPK8 signaling drives a phenotypic switch from DCIS to invasive breast cancer
- PMID: 40468448
- PMCID: PMC12139146
- DOI: 10.1186/s12964-025-02276-y
Matrix stiffness-induced IKBKE and MAPK8 signaling drives a phenotypic switch from DCIS to invasive breast cancer
Abstract
Ductal carcinoma in situ (DCIS) is not life threatening unless it transitions into invasive breast cancer (IBC). However, although breast cancer cell exposure to matrix stiffening in vitro phenotypically mimics the DCIS to IBC switch, the molecular changes driving this switch remains unclear. Here, breast cancer cell kinome activity profiling suggested matrix stiffness-upregulation of 53 kinases, among which 16 kinases were also regulated by integrin β1. Functional validation identified matrix stiffness-activation of inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE) and mitogen-activated protein kinase 8 (MAPK8) signaling as critical for the stiffness-driven IBC phenotype, including for cell proliferation. The IKBKE-inhibitor Amlexanox, clinically utilized for aphthous ulcers, as well as the MAPK8 inhibitor JNK-IN-8, reinstalled the DCIS-like phenotype of breast cancer cells on high matrix stiffness. This suggests that IKBKE and/or MAPK8 inhibitors could enhance the arsenal of treatments to prevent or treat breast cancer.
Keywords: Cellular signaling; Integrin; Kinase; Kinome; Mechanotransduction.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Competing interests: The authors declare no competing interests.
Figures





Similar articles
-
β1-Integrin via NF-κB signaling is essential for acquisition of invasiveness in a model of radiation treated in situ breast cancer.Breast Cancer Res. 2013;15(4):R60. doi: 10.1186/bcr3454. Breast Cancer Res. 2013. PMID: 23883667 Free PMC article.
-
An extracellular matrix stiffness-induced breast cancer cell transcriptome resembles the transition from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC).Biochem Biophys Res Commun. 2023 Apr 30;654:73-79. doi: 10.1016/j.bbrc.2023.03.001. Epub 2023 Mar 2. Biochem Biophys Res Commun. 2023. PMID: 36893606
-
Extracellular Microenvironment Alterations in Ductal Carcinoma In Situ and Invasive Breast Cancer Pathologies by Multiplexed Spatial Proteomics.Int J Mol Sci. 2024 Jun 19;25(12):6748. doi: 10.3390/ijms25126748. Int J Mol Sci. 2024. PMID: 38928454 Free PMC article.
-
Biomarkers Predicting Progression and Prognosis of Ductal Carcinoma In Situ (DCIS).Anticancer Res. 2025 Apr;45(4):1305-1328. doi: 10.21873/anticanres.17518. Anticancer Res. 2025. PMID: 40155037 Review.
-
The Microenvironment in DCIS and Its Role in Disease Progression.Adv Exp Med Biol. 2025;1464:211-235. doi: 10.1007/978-3-031-70875-6_12. Adv Exp Med Biol. 2025. PMID: 39821028 Review.
References
-
- Sung H, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. - PubMed
-
- Shapiro S. Evidence on screening for breast cancer from a randomized trial. Cancer. 1977;39(6 Suppl):2772–82. - PubMed
-
- Tabár L, et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the breast Cancer screening working group of the Swedish National board of health and welfare. Lancet. 1985;1(8433):829–32. - PubMed
-
- Ernster VL, et al. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA. 1996;275(12):913–8. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous